GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hepion Pharmaceuticals HEPA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.13

+7.13%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hepion Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Hepion Pharmaceuticals is based in Red Bank, New Jersey and is incorporated in Delaware. Its shares trade on OTC under the ticker HEPA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Feb 2014
Employees
12
Head office
34 SHREWSBURY AVE., RED BANK, NJ, 07701
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. John BrancaccioExecutive Chairman of the Board, since 2013$502,329
  • Dr. Kaouthar LbiatiInterim Chief Executive Officer, Director, since 2022$273,967
  • Dr. Timothy BlockIndependent Director$274,617
  • Mr. Michael PurcellIndependent Director$174,063

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CRV431 reduces liver fibrosis in experimental models of NASH.
  • CRV431 targets multiple biochemical pathways involved in liver disease progression.
  • CRV431 reduces hepatocellular carcinoma tumor burden in experimental models.

Weaknesses

  • Hepion Pharmaceuticals employs only 12 full-time employees currently.
  • The company is headquartered in Edison, New Jersey.
  • The firm went public on 7 February 2014.

Opportunities

  • CRV431 is being developed for viral hepatitis-induced liver disease.
  • The company focuses on therapies for non-alcoholic steatohepatitis.
  • Hepion develops pleiotropic drug therapy for chronic liver disease.

Threats

  • The company operates in the competitive pharmaceuticals industry.
  • Chronic liver disease treatment requires extensive clinical validation.
  • Non-alcoholic steatohepatitis research faces complex regulatory hurdles.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.